Group 1: Sales Team and Strategy - The company has expanded its sales team to over 200 members, focusing on both online and offline sales channels [2] - The company prioritizes both revenue and profit, viewing them as indicators of market share and profitability [2] - The company has a rich reserve of medical device products, including Class II and Class III devices [2] Group 2: Shareholder and Incentive Plans - The chairman currently has no plans to reduce his shareholding, and any future plans will comply with regulatory disclosure obligations [3] - The company has plans for stock incentives, but the specific timeline for implementation is uncertain [3] Group 3: Financial Position and Market Performance - The company is monitoring potential acquisition targets but has not identified any suitable candidates at this time [3] - The offline business model has a significantly higher net profit margin compared to the online model, and the company aims to enhance offline operations for stable profit contributions [3] - Sales performance during the promotional period in March was satisfactory and aligned with company expectations, with a focus on daily sales [3]

Group 1: Offline Channel Strategy - The company plans to optimize and adjust offline sales channels to improve quality and management capabilities [2] - The transition of distributors from traditional distribution to value-driven sales is a key focus for creating better growth conditions in the offline market [2] - The company aims to expand its offline sales team to lay a talent foundation for long-term business development [2] Group 2: Expansion of Offline Business - The offline business is currently being expanded through two main methods: increasing the number of distributors and direct expansion by the company's sales team targeting large chain terminals [3] - In 2026, the company intends to increase the number of offline partners while ensuring quality [3] Group 3: New Product Development - The company has a robust reserve of new products for 2026, including medical devices and functional skincare products, covering both patch and non-patch forms [3] - Efforts will be made to align the speed and categories of new product launches between online and offline channels [3] Group 4: Performance Guidance - The company does not provide public guidance on offline performance for 2026 but expects a positive start following the optimization and team expansion in 2025 [3]

Group 1: Business Operations and Strategy - In 2025, the company optimized its offline sales channels and improved its management team, leading to enhanced operational capabilities and a solid foundation for 2026 [1] - The sales channels were shifted from traditional distribution to value-driven sales, resulting in a streamlined number of distributors and improved profitability [1] - The offline sales team is divided into three groups: CS and KA channels, professional channels, and OTC channels [1] Group 2: Financial Performance and Projections - Financial data for 2025 is still under audit, with specific figures to be disclosed in the annual report on April 23, 2026 [2] - The offline profit margin is higher than online, with improved profitability due to sales channel optimization [3] - The sales team has grown to over 200 members, reflecting ongoing recruitment efforts [4] Group 3: Product Development and Innovation - The company plans to continue its dual focus on medical devices and functional skincare products, with new product launches expected in various forms including dressings, masks, and creams [5] - Progress is being made on a recombinant type III humanized collagen freeze-dried fiber, which has completed clinical trials and is preparing for submission [6] Group 4: Corporate Governance and Future Plans - The company is considering mergers and acquisitions to enhance R&D capabilities and product offerings, with future updates to be disclosed as per regulatory requirements [7] - The dividend plan for this year has not yet been determined, with an announcement expected on April 23, 2026 [8] - There are ongoing considerations for stock incentive plans, with no current confirmation on implementation [9] - No share reductions have occurred from executives whose restrictions were lifted in February 2025 [9]

Group 1: Online Team and Sales Channels - The company has established operational teams in Shanghai and Hangzhou to enhance online operational efficiency and profitability, focusing on interest e-commerce and shelf e-commerce respectively [2] - All existing sales channels are considered key, with dedicated teams for each channel to deepen exploration and expand new sales channels while improving profitability [3] Group 2: Pricing and Inventory Management - The company's product pricing has remained stable, with improvements in pricing stability due to sales channel optimization [3] - Inventory levels are maintained within a reasonable range, following a sales-driven production principle to ensure timely product supply and minimize operational costs and market risks [3] Group 3: New Product Development - The company has a robust pipeline for new product launches, including medical devices and functional skincare products, with a wide range of formulations and effects [3] - The sales proportion of cosmetic products has increased following the establishment of the Shanghai R&D center, enhancing the product matrix and profitability [3] Group 4: Medical Aesthetics Business - The company is actively advancing its medical aesthetics product layout, with a rich reserve of R&D projects, although future growth as a second growth curve depends on new product output and sales performance [3]

Group 1: Company Changes and Management - In 2025, the company optimized offline sales channels and improved the management team by hiring high-end talent, enhancing overall management capabilities [1] - The management team now effectively complements the existing team, leading to improved performance [1] Group 2: Product Structure - The company's product structure is divided into two main categories: medical devices and cosmetics, with various forms including dressings, masks, lotions, creams, serums, and sprays [1] - The products cover a wide range of functions such as whitening, acne treatment, anti-wrinkle, and repair, showcasing a rich variety of formulations and comprehensive efficacy [1] Group 3: New Product Plans - The company has plans for new products in both medical devices and cosmetics for 2026, with a focus on various forms including dressings, masks, and serums [1] - The actual launch situation will be confirmed later, and stakeholders are encouraged to stay updated [1] Group 4: Sales Channels and Market Strategy - Both online and offline channels are considered main battlegrounds for the company, with significant efforts made in offline channel optimization in 2025 [2] - The company is well-prepared for offline business in 2026, aiming for improved performance in this area [2] Group 5: Product Launch and Certification - The company had a successful product launch in 2025 and is optimistic about new products in 2026, with plans for effective promotion and marketing [2] - The timeline for certification of three types of injection products depends on regulatory approval, and updates will be disclosed accordingly [2] Group 6: Shareholder Information - The chairman currently has no plans to reduce shareholding, and any future changes will be disclosed in compliance with regulatory requirements [2] - The dividend plan for this year has not yet been determined, with an announcement expected on April 23, 2026 [2]

Group 1: Management and Talent Development - The company has been continuously attracting high-end talent to enhance the management team's structure and capabilities, aiming for sustainable development [1] - The management team is expected to further strengthen talent development initiatives [1] Group 2: Medical Aesthetics Progress - The clinical trial for the "recombinant type III humanized collagen freeze-dried fibers" has been completed, and the company is preparing to submit registration materials [1] Group 3: E-commerce Operations - The e-commerce team is divided into interest e-commerce and shelf e-commerce, with operations based in Shanghai and Hangzhou respectively [2] - The Shanghai team focuses on platforms like Douyin, while the Hangzhou team manages Tmall operations [2] Group 4: Sales Performance and Promotions - The performance during the 3.8 promotional period met expectations, with a focus on daily sales [2] - The company anticipates that the 3.8 promotional activities will positively impact overall performance [2] Group 5: New Product Development - The company plans to continue a dual approach in new product development, focusing on medical devices and functional skincare products [2] - New product forms will include dressings, masks, lotions, creams, and serums, with specifics to be confirmed in 2026 [2] Group 6: Pricing and Cost Management - Product pricing has remained stable, with fluctuations within a reasonable range during promotional periods [2] - The company employs refined operational strategies to control online business costs while enhancing profitability [2] Group 7: Dividend Policy - The dividend proposal for the current year has not yet been determined, with an announcement expected on April 23, 2026 [2]

Group 1: Sales and Marketing Strategies - The company is actively promoting its brand and products ahead of the International Women's Day sales event, aiming for strong sales performance [2] - The company plans to launch new products across various formats, including water, lotion, cream, and essence, in addition to upgrading existing products [2] Group 2: E-commerce Operations - The company has established e-commerce teams in Harbin, Shanghai, and Hangzhou, with specific teams focusing on different platforms like Douyin and Tmall [3] - The profitability of Tmall and Douyin will be assessed after the annual report, but both platforms have shown rapid growth and alignment with company expectations [3] Group 3: Product Development and Medical Devices - The company continues to develop medical devices, focusing on both Class II and Class III products, leveraging a collaborative R&D model [3] - The company aims to enhance its medical device product matrix to improve profitability [3] Group 4: Inventory and Production Management - The company follows a sales-driven production principle to manage inventory effectively, minimizing operational costs and market risks [4] - There is no significant risk of inventory backlog due to the company's efficient production planning [4] Group 5: Future Outlook and Corporate Governance - The company has plans for stock incentives, but the timing and implementation remain uncertain [4] - The chairman currently has no plans to reduce his shareholding in the company [4]

Product Structure - The company's products are mainly divided into two categories: medical devices and functional skincare products [2] - Non-patch products include various forms such as water, essence, lotion, spray, lyophilized, and single-use essence [2] Non-Patch Product Revenue - The revenue share of non-patch products is continuously increasing following the establishment of the Shanghai R&D center, which has accelerated the speed of new product launches [2] Medical Device Progress - The company is making significant progress with three types of medical devices, including recombinant type III humanized collagen protein lyophilized fibers and dressings, with clinical trials completed for the former [3] - The injectable recombinant type III humanized collagen protein gel is expected to start clinical trials this year [3] Pricing Stability - The pricing situation for the company's products is stable, with overall price differences across channels being controllable [3] - Price fluctuations among mainstream channels remain within a reasonable range, with promotional strategies employed to balance sales and pricing during peak periods [3] Aesthetic Medicine Strategy - The company is strategically entering the aesthetic medicine sector due to its pharmaceutical background, aligning medical device products with existing offerings [3] - The company is monitoring potential acquisition targets in the aesthetic medicine field and will adhere to regulatory disclosure obligations for any developments [3] Dividend Policy - The company has maintained a positive attitude towards returning profits to investors through cash dividends since its listing, although specific dividend amounts will depend on performance and financial planning [3] Equity Incentives - The company has plans for equity incentives as the management team evolves, with intentions to disclose specific details in future announcements [3]

Core Viewpoint - Fuhua Jia (301371) is a specialized skin care product company focused on the research, production, and sales of professional skin care products, which are divided into medical device products and functional skin care products [1] Group 1: Product Offerings - The company's product forms include masks, waters, serums, lotions, sprays, freeze-dried products, and single-use serums [1] Group 2: Sales Strategy - The company employs an omnichannel strategy for sales, integrating both online and offline channels [1] - Online channels include major e-commerce and social media platforms such as Tmall, Douyin, JD.com, and Pinduoduo [1] - Offline channels penetrate cosmetic specialty stores, large supermarkets, chain pharmacies, beauty institutions, and medical institutions, creating a comprehensive market reach network [1]

Core Viewpoint - Chuang'er Bio has officially terminated its IPO preparation for the Beijing Stock Exchange after three years of efforts, marking a significant setback in its capital market ambitions [1]. Company Overview - Chuang'er Bio specializes in medical devices and bio-skincare products, having developed large-scale sterile extraction technology for bio-medical grade active collagen. The company holds two Class III and two Class II medical device registration certificates [2]. - The market share of Chuang'er Bio's collagen products in China's pharmaceutical-grade collagen market was 3.04% in 2017, 3.40% in 2018, and 5.23% in 2019 [2]. IPO Journey - The company's IPO journey has faced challenges, including an attempt to list on the Sci-Tech Innovation Board in 2020, which was followed by a withdrawal of the application in 2021 and a subsequent shift to the Beijing Stock Exchange [2]. - In July 2023, Chuang'er Bio signed a listing advisory agreement with Guotou Securities and submitted the listing advisory filing materials to the Guangdong Securities Regulatory Bureau. However, due to unresolved shareholder equity freeze issues, the advisory agreement was terminated on December 25, 2025 [2][3]. Shareholder Issues - The company did not disclose details about the shareholder equity freeze in its announcement, but it is directly related to its second-largest shareholder, Ding Yumei, who holds 365,360 shares, accounting for 4.30% of the company. This portion of shares is entirely frozen and not tradable [3]. - Ding Yumei is also known as the ex-wife of Xu Jiayin, the former chairman of the now-defunct China Evergrande Group. Chuang'er Bio previously collaborated with Ding Yumei's company on a skincare product project, which was ultimately terminated, leading to the recovery of a prepayment of 5 million yuan [5][6]. Legal and Financial Context - Ding Yumei's equity freeze is linked to the debt liquidation issues surrounding Evergrande. In 2022, she was reported to have reached a "technical divorce" with Xu Jiayin, interpreted as a financial separation to avoid debt liabilities [7]. - In March 2024, a lawsuit was initiated by the liquidators of China Evergrande to recover approximately $6 billion in dividends and compensation from Xu Jiayin, Ding Yumei, and several former executives. This legal action has resulted in global asset freezing orders against Ding Yumei [7].